Cancer-related pain
Conditions
Interventions
Group A:Medication, oral hydromorphone hydrochloride sustained release tablets once a day
Group B:Medication, oral morphine hydrochloride sustained release tablets every 12 hours
Sponsors
Affiliated Cancer Hospital of Chongqing University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Subjects voluntarily sign informed consent for this study; 2.Malignant tumor diagnosed by cytopathology or histopathology; 3.Age 18-80, gender unlimited; 4.Patients with clear consciousness ; 5.Cancer-related pain with an NRS score >=4 in the last 24 hours; 6.Patients requiring daily opioid analgesics (MEDD>=40mg) to control moderate to severe cancer pain; 7.The ECOG-PS score of physical condition is 0~3 points;
Exclusion criteria
Exclusion criteria: 1.Patients are non-cancer pain patients or the cause of the pain is unclear; 2.Patients with paralytic ileus; 3.Patients with brain metastases or meningeal metastases accompanied by clinical manifestations of intracranial space occupying effect (headache, dizziness, nausea, vomiting, disturbance of consciousness, seizures, etc.); 4.Abnormal liver and kidney function results (such as creatinine >= 2 times the upper limit of normal, ALT or AST>= 2.5 times the upper limit of normal (liver metastasis patients or primary liver cancer >= 5 times the upper limit of normal), or liver function Child C grade, etc.); 5.Patients with cognitive dysfunction; 6.Patients who cannot be taken orally; 7.Patients who are allergic to opioids; 8.Pregnant or lactating women or patients who plan to have a baby (including men) within 3 months; 9.Patients who are participating in a clinical study (including the drug in the trial) within 1 month before the trial; 10.Patients who chose to receive chemoradiotherapy anti-tumor therapy during the study period; 11.Patients who received radiation therapy at the site of pain within 7 days prior to the trial; 12.Diseases and conditions that researchers consider ineligible.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| D6 pain score after drug conversion; | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient conversion success rate;Number of break through pain per day;Patient satisfaction evaluation;Score of life quality;Incidence of adverse reactions; | — |
Countries
China
Contacts
Public ContactHuiqing Yu
Chongqing University Cancer Hospital
Outcome results
None listed